Project Grant R21CA309375
Award Date 3/19/26
Completion Date 2/28/27
Dollars Obligated $385K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boulder, CO 80303, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $584,510 to the University of Colorado-Denver under the Cancer Biology Research program (CFDA 93.396) on September 12, 2025, for a project period extending through August 31, 2029. This Project Grant (R50 funding mechanism) supports the Human Immune Monitoring Shared Resource (HIMSR), a specialized facility within the University of Colorado Cancer Center that provides comprehensive services to cancer researchers. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $491,315 to the University of Colorado-Denver under the Cancer Biology Research program (CFDA 93.396) on September 12, 2025, for a project period extending through August 31, 2029. The award supports the Functional Genomics Shared Resource (FGSR) at the University of Colorado Cancer Center in advancing functional genomics and cell engineering technologies for cancer research. Under the direction of Dr. Molishree Joshi,...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded J. David Gladstone Institutes a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, through May 31, 2030. This award supports the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy outcomes in colorectal cancer. The research addresses the limited efficacy of Chimeric Antigen Receptor (CAR) T cell therapies and...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $418,176 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This award supports the continued advanced development and validation of programmable nucleic acid cytometry technology, specifically building upon the Institute's prior work with Programmable Enrichment via RNA Fluorescence In Situ Hybridization...
- Federal Grant Award Summary The National Cancer Institute awarded a $661,721 Project Grant to the University of California, San Diego, under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. The award supports fundamental research focused on systematic functional mapping and interrogation of intrinsically disordered regions (IDRs) in oncogenic proteins. The research employs high-throughput functional screening technologies and computational...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on aberrant RNA splicing mechanisms in leukemia. The research, initiated August 18, 2025 and extending through July 31, 2032, focuses on understanding how mutations in RNA splicing factors drive the development of hematologic malignancies, including myelodysplastic...